The VERIFY trial explores rusfertide to manage polycythemia vera without causing iron deficiency symptoms, Dr. Aaron Gerds ...

Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with ...

Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels ...

Protagonist Therapeutics Inc. (NASDAQ:PTGX) is one of the best mid cap growth stocks to invest in now. Just as June began, ...

Summary for Physicians: Complementary Role of Hepcidin Mimetics in PV Therapy. Hepcidin mimetics, such as rusfertide, offer a novel mechanism of action that can complement existing therapeutic ...

为解决水产养殖中致病性弧菌感染的防控难题，研究人员从丝鳍银鲈(Gerres filamentosus)中鉴定出一种新型hepcidin异构体(rGf-Hep)，通过膜去极化、膜通透性改变及ROS生成等多重机制，显著抑制副溶血弧菌(V. parahaemolyticus)等病原体，其非细胞毒性特性为开发安全高效的抗弧菌制剂提供新思路。

Silence Therapeutics presents additional data from phase 1 study of divesiran as potential first-in-class siRNA treatment for polycythemia vera: London Monday, June 16, 2025, 18:0 ...

For patients with a rare type of blood cancer, treatment might finally be coming out of the Dark Ages. People with the chronic condition polycythemia vera make too many red blood cells, thickening ...

A team identified herpes virus saimiri, which infects the T cells of squirrel monkeys, as a source of proteins that activate pathways in T cells that are needed to promote T cell survival.